HL Pharma shares pharmaceutical news, industry updates and practical guidance for sponsors, healthcare providers and supply partners across Australia.
Clinical trial supply in Australia operates across several regulatory/quality frameworks. Weaknesses in storage, transport, documentation or handover controls can delay supply or increase product loss.
read moreFor patients with a serious or life-limiting condition, treatment options don’t always wait for a medicine to be registered in Australia. A Managed Access Program (MAP) is one of the pathways that can bridge that gap.
read moreWhen a trial closes, the supply obligation does not. Patients on continued access need the same standard of supply as they received during the trial itself. That is where most programmes quietly struggle.
read moreAccessing medicines that are not registered in Australia involves navigating established TGA regulatory pathways, each with distinct eligibility, documentation and compliance requirements.
read moreHL Pharma becomes a Strategic Partner of ARCS Australia, helping us contribute more actively to the conversations shaping access to medicines, clinical supply and patient support across Australia.
read moreVeterinary medicine shortages are impacting oncology, ophthalmology and critical care. Learn how veterinary hospitals can maintain continuity of care through controlled pathways.
read more
